GILD vs VNDA · P/E 18, rev $7.80B vs rev $102.2M
Gilead Sciences Inc (GILD) versus Vanda Pharmaceuticals Inc (VNDA) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Vanda Pharmaceuticals Inc (VNDA) is a biotechnology company listed on NASDAQ.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported VNDA revenue for 2026-06-30 was $102.2M. Net income was -$111.1M. Revenue was up 97.7% from 2026-03-31 to 2026-06-30. VNDA currently screens at market cap $358.4M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. VNDA currently screens at market cap $358.4M.
Not investment advice. Open the GILD and VNDA stock pages for the full models.
Not investment advice.